A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of naldemedine in cancer patients with opioid-induced constipation

Trial Profile

A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of naldemedine in cancer patients with opioid-induced constipation

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Oct 2017

At a glance

  • Drugs Naldemedine (Primary)
  • Indications Constipation
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms COMPOSE IV
  • Sponsors Shionogi
  • Most Recent Events

    • 02 Oct 2017 Results published in the Journal of Clinical Oncology
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress.
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top